Episode #118 | The Cost of Life: AI vs. Artificial Organs

We put a price tag on “saving a life” by comparing blockbuster AI spending with the tiny budgets aimed at artificial organs and organ regeneration. We walk through why bioprinted kidneys are so hard to build, why kidney failure is such a massive economic burden, and what smarter near-term bets could look like. 

This podcast is just a summary. 

Read the full article here: 

https://3dheals.com/how-much-should-artificial-organs-be-thoughts-from-agi/

Highlights:
• the jaw-dropping gap between AI spending and artificial organ funding 
• why artificial organs are not one problem but many 
• examples of nearer-term engineered tissues like skin, cartilage, and vascular grafts 
• why kidneys are the biggest case study on need and scale 
• the real cost drivers behind a bioprinted kidney, from cell manufacturing to regulation 
• the trade-off between long-term moonshots and short-term healthcare wins 
• how resource allocation shapes the future we end up living in 

Transcript

The Cost Of Saving A Life

SPEAKER_01 0:00

How much does it cost to save a life? Here's a wild comparison. OpenAI spent $22 billion in 2025 to generate $13 billion in revenue, while the most ambitious US government program for artificial organs got just $65 million. That's what we're unpacking today.

SPEAKER_00 0:21

That's such a stark contrast. It's almost hard to wrap your head around billions for AI, but just a fraction of that for something as life-changing as artificial organs. Where do we even start?

Why Artificial Organs Are Hard

SPEAKER_01 0:35

Well, let's start with the basics. Artificial organs, especially biologics-based ones, are seen as the holy grail of tissue engineering. They're not impossible to create, no laws of physics are being broken here, but the challenges are immense. It's about cost, complexity, and time.

SPEAKER_00 0:55

And when you say cost, we're not just talking about a few million dollars here and there. We're talking about potentially billions to develop something like a bioprinted kidney, right?

SPEAKER_01 1:06

Exactly.

Simple Tissues Versus Solid Organs

SPEAKER_01 1:07

But here's the thing artificial organs aren't a monolithic category. Some are much simpler and cheaper to develop than others. For example, companies like Organogenesis have already commercialized cell-based skin products. Nanochon is working on 3D printed cartilage implants, and Hemocyte is developing vascular grafts. These are relatively straightforward compared to something like a kidney or a heart.

SPEAKER_00 1:35

Oh, so the complexity really ramps up when you get into solid organs, like kidneys or hearts. Those require dense vascularization, multiple cell types, and intricate structures. It's a whole different ballgame.

Kidney Demand And Dialysis Costs

SPEAKER_01 1:49

That's right. And the kidney is a particularly interesting case study. The medical need is enormous. There are over 120,000 people on organ waiting lists in the U.S., and kidneys make up the majority of that demand. But only about 45,000 transplants are performed each year. The shortfall is staggering.

SPEAKER_00 2:08

And the alternatives like dialysis are incredibly expensive. I read that dialysis costs around $90,000 to $100,000 per patient per year in the US. That adds up fast.

SPEAKER_01 2:23

It really does. At the system level, renal replacement therapy consumes 3-5% of annual healthcare budgets in many countries. By 2030, the global population with end-stage kidney disease could reach 14.5 million people. That's a massive economic and healthcare burden.

SPEAKER_00 2:43

So if the need is so clear and the costs are so high, why isn't more money being funneled into developing artificial kidneys?

The Funding Gap And Priorities

SPEAKER_00 2:50

What's holding us back?

SPEAKER_01 2:52

That's the billion-dollar question. Literally. The funding disparity is shocking. OpenAI spent $22 billion in 2025 alone, while the entire ARPAH print program, which focuses on organ regeneration, got just $65 million. It's a 330 to 1 spending ratio in favor of AI.

SPEAKER_00 3:16

That's just mind-boggling. And when you think about the broader healthcare landscape, it gets even more frustrating. The US spent $5.3 trillion on healthcare in 2024, which was 18% of GDP. But the regenerative medicine sector, which could actually reduce that burden, was estimated at just $45 billion globally in 2025. That's less than 1% of US healthcare spending in a single year.

SPEAKER_01 3:47

It's a glaring imbalance, and it's not just about money, it's about priorities.

Why Bioprinted Kidneys Cost So Much

SPEAKER_01 3:53

Developing a bioprinted kidney isn't just expensive, it's also incredibly complex. The process involves cell manufacturing, bioinks, perfusion systems, quality control, animal studies, GMP scale-up, surgery, and regulatory work. It's a monumental effort.

SPEAKER_00 4:13

And even if you get through all that, the final perpatient cost for a first-generation product will likely be sky high. We're talking six figures, maybe even higher than today's transplant costs. It's not just about making the organ, it's about making it affordable and scalable.

SPEAKER_01 4:31

Exactly.

Long Term Moonshots Or Near Term Wins

SPEAKER_01 4:33

And that brings us to a tough question. Should we be pouring billions into developing the most ambitious versions of artificial organs as quickly as possible, or should we focus on cheaper, scalable interventions that can help more people in the near term?

SPEAKER_00 4:48

That's such a difficult trade-off. On one hand, pushing for fully tissue-engineered kidneys could save countless lives in the long run. But on the other hand, focusing on simpler solutions, like improving dialysis or developing less complex engineered tissues, might save more lives in the short term.

SPEAKER_01 5:08

It's a classic case of long-term versus short-term thinking. And the parallels with AGI are striking. Just because something is possible doesn't mean it's the best use of resources right now. Sometimes the rational choice is to focus on what can make the biggest impact in the shortest amount of time.

SPEAKER_00 5:27

And that's where the conversation gets really interesting.

Choosing The Future We Build

SPEAKER_00 5:30

What kind of future do we want to build? And how do we allocate our resources to get there? It's not just about what's possible, it's about what's practical and impactful.

SPEAKER_01 5:42

Exactly. And that's why this discussion is so important. Whether we're talking about artificial organs or AGI, these are questions of priorities, not just possibilities. The stakes couldn't be higher.

SPEAKER_00 5:54

Agreed. Let's hope we can find a balance that serves both immediate needs and long term ambitions.

SPEAKER_01 6:00

Well said.